...

Download the PDF: Hall_Matthew_oral_history (137kB)

Read a paper:

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses, J. Clin Immunol, 2021 Jul; 41(5): 906-913.  doi: 10.1007/s10875-021-00997-6. Epub 2021 Mar 16.

Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2, Trends Pharamacol Sci, 2020 Nov; 41(11): 815-829.  doi: 10.1016/j.tips.2020.07.004. Epub 2020 Jul 31.

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19, ACS Cent Sci, 2020 May 27; 6(5): 672-683.  doi: 10.1021/acscentsci.0c00489. Epub 2020 May 4.

Dr. Matthew Hall

Behind the Mask

May 20, 2021

Barr: Good afternoon. Today is May 20, 2021. My name is Gabrielle Barr, and I am the archivist with the Office of NIH History and Stetten Museum, and today I have the pleasure of speaking with Dr. Matthew Hall.  Dr. Hall is the Biology Group Leader and Director in the Division of Pre-Clinical Innovation in the Early Translation Branch of NCATS, and today he will be speaking about some of his COVID work and experiences. Thank you very much for being with me.

Hall: Thank you, I am really happy to meet you. It is nice to be here.

See end of interview. The list is extensive.

Dr. Matthew Hall

Behind the Mask

May 20, 2021

Barr: Good afternoon. Today is May 20, 2021. My name is Gabrielle Barr, and I am the archivist with the Office of NIH History and Stetten Museum, and today I have the pleasure of speaking with Dr. Matthew Hall.  Dr. Hall is the Biology Group Leader and Director in the Division of Pre-Clinical Innovation in the Early Translation Branch of NCATS, and today he will be speaking about some of his COVID work and experiences. Thank you very much for being with me.

Hall: Thank you, I am really happy to meet you. It is nice to be here.

Barr: It is nice to finally speak to you as well. I have seen your name in different publications as well as on different emails. It is nice to, finally, put a face to the name. To begin, will you please speak about some of your findings from a really early study that you are a part of: Barr: It is nice to finally speak to you as well. I have seen your name in different publications as well as on different emails. It is nice to, finally, put a face to the name. To begin, will you please speak about some of your findings from a really early study that you are a part of: “Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Beta-Corona Viruses”?

...

Hall: Thank you, Gabrielle. It was really nice to talk to you and meet you today.

Read a paper:

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses, J. Clin Immunol, 2021 Jul; 41(5): 906-913.  doi: 10.1007/s10875-021-00997-6. Epub 2021 Mar 16.

Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2, Trends Pharamacol Sci, 2020 Nov; 41(11): 815-829.  doi: 10.1016/j.tips.2020.07.004. Epub 2020 Jul 31.

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19, ACS Cent Sci, 2020 May 27; 6(5): 672-683.  doi: 10.1021/acscentsci.0c00489. Epub 2020 May 4.

Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19, ACS Cent Sci, 2020 Jun 24; 6(6): 1009.   doi: 10.1021/acscentsci.0c00747. Epub 2020 Jun 16.

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19, ACS Pharmacol. Transl. Sci. 2020, 3, 5, 997–1007, 

Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling,  Nat Commun 12, 113 (2021). https://doi.org/10.1038/s41467-020-20383-x

Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay, ACS Pharmacol. Transl. Sci. 2020, 3, 6, 1352–1360

Synergistic and Antagonistic Drug Combinations against SARS-CoV-2, Mol Ther., 2021 Feb 3; 29(2): 873-885.  doi:                10.1016/j.ymthe.2020.12.016. Epub 2020 Dec 15

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2, Front. Pharmacol., 25 January 2021 https://doi.org/10.3389/fphar.2020.592737

Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States, Sci Trans Med, 2021 Jul 7;13(601):eabh3826.  doi: 10.1126/scitranslmed.abh3826. Epub 2021 Jun 22

Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein, ACS Med Chem Lett, 2021 Jul 28; 12(8): 1267-1274. oi: 10.1021/acsmedchemlett.1c00263. eCollection 2021 Aug 12.

Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants, ACS Pharmacol Trans Sci, 2021 Sep 17; 4(5): 1675-1688.  doi: 10.1021/acsptsci.1c00176. eCollection 2021 Oct 8.

Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19, ACS Pharmacol Trans Sci, 2021 Apr 2; 4(3): 1124-1135.  doi: 10.1021/acsptsci.0c00221. eCollection 2021 Jun 11.

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit, J Infect Dis, 2021 Jul 15; 224(Supplement_1): S1-S21.  doi: 10.1093/infdis/jiab305.

The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules, ACS Infect Dis, 2021 Jun 11 ;7(6): 1389-1408. doi: 10.1021/acsinfecdis.0c00349. Epub 2020 Dec 21.